Citadel Advisors
FULC icon

Citadel Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Citadel Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161K Sell
21,000
-5,500
-21% -$51K ﹤0.01% 11621
2025
Q4 		$300K Sell
26,500
-7,900
-23% -$80.4K ﹤0.01% 10155
2025
Q3 		$316K Buy
34,400
+15,100
+78% +$109K ﹤0.01% 10235
2025
Q2 		$133K Buy
19,300
+4,200
+28% +$22.5K ﹤0.01% 11071
2025
Q1 		$43.5K Sell
15,100
-114,500
-88% -$421K ﹤0.01% 12449
2024
Q4 		$609K Sell
129,600
-65,400
-34% -$241K ﹤0.01% 8124
2024
Q3 		$696K Buy
195,000
+79,300
+69% +$588K ﹤0.01% 7555
2024
Q2 		$717K Buy
115,700
+62,900
+119% +$476K ﹤0.01% 7313
2024
Q1 		$498K Sell
52,800
-279,300
-84% -$2.49M ﹤0.01% 8409
2023
Q4 		$2.24M Sell
332,100
-18,000
-5% -$79.9K ﹤0.01% 5161
2023
Q3 		$1.55M Buy
350,100
+10,100
+3% +$44.1K ﹤0.01% 5692
2023
Q2 		$1.12M Sell
340,000
-7,800
-2% -$22.9K ﹤0.01% 6223
2023
Q1 		$991K Buy
347,800
+25,400
+8% +$228K ﹤0.01% 6803
2022
Q4 		$2.35M Sell
322,400
-6,600
-2% -$43K ﹤0.01% 5180
2022
Q3 		$2.66M Sell
329,000
-147,500
-31% -$1.06M ﹤0.01% 5045
2022
Q2 		$2.33M Buy
476,500
+433,500
+1,008% +$4.24M ﹤0.01% 5244
2022
Q1 		$1.02M Buy
43,000
+28,700
+201% +$406K ﹤0.01% 7656
2021
Q4 		$253K Sell
14,300
-3,700
-21% -$73.3K ﹤0.01% 11324
2021
Q3 		$508K Buy
+18,000
New +$341K ﹤0.01% 9821

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Citadel Advisors's FULC Position: Q1 2026 in Review

Citadel Advisors increased its Fulcrum Therapeutics (FULC) stake by 7.1% in Q1 2026, buying an estimated $793K and bringing the position to 1,292,486 shares worth $9.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Citadel Advisors first reported a position in FULC in Q2 2021 and has held it in 20 quarters since. The position peaked at $13.7M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Citadel Advisors held 1,292,486 shares of Fulcrum Therapeutics worth $9.91M as of Q1 2026.
  • Citadel Advisors bought 85,482 Fulcrum Therapeutics shares in Q1 2026, an estimated $793K.
  • Fulcrum Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3271 holding.
  • Citadel Advisors first reported a position in Fulcrum Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Citadel Advisors's Fulcrum Therapeutics position peaked at $13.7M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.